The National Cancer Institute awarded $2.9 million to the University of Oklahoma to fund clinical trials testing RedHill Biopharma's investigational drug opaganib combined with CAR T-cell therapy for ultra-high-risk multiple myeloma. The trials aim to evaluate safety and preliminary effectiveness, potentially improving immune cell cancer-fighting ability. This study could lead to longer-lasting treatment responses for patients with poor prognosis. RedHill will supply opaganib, while the University of Oklahoma will manufacture CAR T cells on campus, reducing costs and time.
The $2.9 million NCI grant for RedHill's opaganib and CAR T-cell combination in multiple myeloma is the subject, with Pluang's Health sector data providing context. As of Oct 19, 2026 18:01 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 73 rose and 47 fell. Notable movers include AMLX at USD 26.86 (+1.97%), RLAY at USD 16.59 (+1.90%), and BFLY at USD 7.38 (+1.86%).
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
